Congratulations on this landmark endovascular stroke trial!
Compared to the recent IMS III trial which enrolled patients with NIHSS >=10 (later amended to include NIHSS 8-9 if baseline CTA or MRA showed ICA, M1 or basilar occlusion), MR CLEAN enrolled patients with a broader range of severity (NIHSS >=2). A critical inclusion criterion of MR CLEAN is the presence of proximal occlusion in the anterior circulation (ICA, M1, M2), which closely resembles real-life practice.
While IMS III aimed to capture patients with a high likelihood of proximal occlusion by focusing on high NIHSS scores, it did not require baseline vessel imaging (only 47% had baseline CTA) and 21% of treatment group did not have a retrievable thrombus on angiogram, likely diluting treatment effects.
How many patients in the study had NIHSS of 2-7 and how did treatment group do compared to control? An example would be a left M1 clot with moderate aphasia (NIHSS =2), with a large penumbra.